| 生物活性 | Neuronostatin-13 human is a 13-amino-acid peptide hormone encoded by the somatostatin gene that plays an important role in regulating hormonal and cardiac functions. |
| 体外研究 (In Vitro) |
Neuronostatin-13 human is a 13-amino acid peptide hormone encoded by the somatostatin gene and plays an important role in the regulation of hormonal and cardiac function. Treatment with Neuronostatin-13 human (1,000 nM) enhances low-glucose-induced glucagon release compare with islets treated with control medium alone. Treatment with Neuronostatin-13 human for 1 h leads to a significant increase in the accumulation of glucagon mRNA compare with vehicle-treated control cells. In αTC1-9 α-cells, treatment with 100 nM Neuronostatin-13 human leads to an increase in phosphorylated PKA at 30 and 40 min. |
| 体内研究 (In Vivo) |
Infusion with Neuronostatin-13 human delays glucose clearance in the rat model, such that blood glucose levels in Neuronostatin-13 human-treated animals are significantly higher at 1 and 10 min following intra-arterial injection of a glucose bolus. Chocardiographic measurement reveals a remarkable drop in heart rate after 3-, 6- and 12-hr of Neuronostatin-13 human challenge. In addition, Neuronostatin-13 human treatment significantly decreases left ventricular end-systolic diameter (LVESD) and fractional shortening without affecting left ventricular end-diastolic diameter (LVEDD) between 6 and 12 hrs following Neuronostatin-13 human challenge, the effect of which returns to basal level 18-hr after Neuronostatin-13 human treatment. |
| 性状 | 固体 |
| 颜色 | White to off-white |
| 分子量 | 1415.68 |
| 分子式 | C64H110N20O16 |
| CAS No. | 1096485-24-3 |
| 储存方式 | Sealed storage, away from moisture
*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
|||||||||||||||||||||||||||
| 运输条件 | Room temperature in continental US; may vary elsewhere. | |||||||||||||||||||||||||||
|
溶液配制表
|
||||||||||||||||||||||||||||
|
H2O 中的溶解度 : 25 mg/mL (17.66 mM; 超声助溶)
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。
|
||||||||||||||||||||||||||||
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:
比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
© 2026 MolStrong. 保留所有权利。粤ICP备2023004355号
可通过CAS号进行批量搜索,一行一个CAS号